KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer

Kazunori Kamiya, Masazumi Watanabe, Mitsutomo Kohno, Yotaro Izumi, Hirohisa Horinouchi, Masafumi Kawamura, Naoki Shimada, Hiroaki Nomori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and objective: Both Krebs von den Lungen-6 (KL-6) and carcinoembryonic antigen (CEA) are known to be tumour markers in non-small cell lung cancer (NSCLC). The aim of the present study was to assess whether or not intrabronchial epithelial lining fluid (ELF) levels of these markers predicted tumour response better than serum levels in patients with advanced NSCLC treated with gefitinib. Methods: ELF samples were obtained both from near the tumour and from the contralateral lung using a bronchoscopic microsampling technique, before and 2 weeks after the start of gefitinib treatment. Serum samples were taken concurrently. Among the 22 patients enrolled in the study, 14 (64%) showed partial responses or stabilization of disease with gefitinib treatment (treatment responders), while 8 (36%) showed progression of disease (treatment non-responders), 4 weeks after the start of treatment. Results: ELF KL-6 levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.011), whereas there was a marginal increase in the treatment non-responders group (P = 0.049). ELF CEA levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.004), whereas there was no significant change in the treatment non-responders group. For both markers, neither the serum levels nor the levels in contralateral ELF showed any significant changes in either group of patients. Conclusions: Both KL-6 and CEA levels in ELF near the tumour predicted tumour response in NSCLC patients treated with gefitinib, whereas serum levels did not. Intrabronchial epithelial lining fluid levels of KL-6 and CEA near tumours, as assessed by bronchoscopic microsampling, predicted tumour response in patients with advanced non-small cell lung cancer who were treated with gefitinib, whereas serum levels did not.

Original languageEnglish
Pages (from-to)976-982
Number of pages7
JournalRespirology
Volume16
Issue number6
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Carcinoembryonic Antigen
Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Tumor Biomarkers
Serum
gefitinib
Disease Progression
Biomarkers
Lung

Keywords

  • carcinoembryonic antigen
  • epithelial lining fluid
  • Krebs von den Lungen-6
  • non-small cell lung cancer
  • tumour response

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. / Kamiya, Kazunori; Watanabe, Masazumi; Kohno, Mitsutomo; Izumi, Yotaro; Horinouchi, Hirohisa; Kawamura, Masafumi; Shimada, Naoki; Nomori, Hiroaki.

In: Respirology, Vol. 16, No. 6, 08.2011, p. 976-982.

Research output: Contribution to journalArticle

Kamiya, K, Watanabe, M, Kohno, M, Izumi, Y, Horinouchi, H, Kawamura, M, Shimada, N & Nomori, H 2011, 'KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer', Respirology, vol. 16, no. 6, pp. 976-982. https://doi.org/10.1111/j.1440-1843.2011.02009.x
Kamiya, Kazunori ; Watanabe, Masazumi ; Kohno, Mitsutomo ; Izumi, Yotaro ; Horinouchi, Hirohisa ; Kawamura, Masafumi ; Shimada, Naoki ; Nomori, Hiroaki. / KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. In: Respirology. 2011 ; Vol. 16, No. 6. pp. 976-982.
@article{b48458e2a49e43a291e324a7948f7c24,
title = "KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer",
abstract = "Background and objective: Both Krebs von den Lungen-6 (KL-6) and carcinoembryonic antigen (CEA) are known to be tumour markers in non-small cell lung cancer (NSCLC). The aim of the present study was to assess whether or not intrabronchial epithelial lining fluid (ELF) levels of these markers predicted tumour response better than serum levels in patients with advanced NSCLC treated with gefitinib. Methods: ELF samples were obtained both from near the tumour and from the contralateral lung using a bronchoscopic microsampling technique, before and 2 weeks after the start of gefitinib treatment. Serum samples were taken concurrently. Among the 22 patients enrolled in the study, 14 (64{\%}) showed partial responses or stabilization of disease with gefitinib treatment (treatment responders), while 8 (36{\%}) showed progression of disease (treatment non-responders), 4 weeks after the start of treatment. Results: ELF KL-6 levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.011), whereas there was a marginal increase in the treatment non-responders group (P = 0.049). ELF CEA levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.004), whereas there was no significant change in the treatment non-responders group. For both markers, neither the serum levels nor the levels in contralateral ELF showed any significant changes in either group of patients. Conclusions: Both KL-6 and CEA levels in ELF near the tumour predicted tumour response in NSCLC patients treated with gefitinib, whereas serum levels did not. Intrabronchial epithelial lining fluid levels of KL-6 and CEA near tumours, as assessed by bronchoscopic microsampling, predicted tumour response in patients with advanced non-small cell lung cancer who were treated with gefitinib, whereas serum levels did not.",
keywords = "carcinoembryonic antigen, epithelial lining fluid, Krebs von den Lungen-6, non-small cell lung cancer, tumour response",
author = "Kazunori Kamiya and Masazumi Watanabe and Mitsutomo Kohno and Yotaro Izumi and Hirohisa Horinouchi and Masafumi Kawamura and Naoki Shimada and Hiroaki Nomori",
year = "2011",
month = "8",
doi = "10.1111/j.1440-1843.2011.02009.x",
language = "English",
volume = "16",
pages = "976--982",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer

AU - Kamiya, Kazunori

AU - Watanabe, Masazumi

AU - Kohno, Mitsutomo

AU - Izumi, Yotaro

AU - Horinouchi, Hirohisa

AU - Kawamura, Masafumi

AU - Shimada, Naoki

AU - Nomori, Hiroaki

PY - 2011/8

Y1 - 2011/8

N2 - Background and objective: Both Krebs von den Lungen-6 (KL-6) and carcinoembryonic antigen (CEA) are known to be tumour markers in non-small cell lung cancer (NSCLC). The aim of the present study was to assess whether or not intrabronchial epithelial lining fluid (ELF) levels of these markers predicted tumour response better than serum levels in patients with advanced NSCLC treated with gefitinib. Methods: ELF samples were obtained both from near the tumour and from the contralateral lung using a bronchoscopic microsampling technique, before and 2 weeks after the start of gefitinib treatment. Serum samples were taken concurrently. Among the 22 patients enrolled in the study, 14 (64%) showed partial responses or stabilization of disease with gefitinib treatment (treatment responders), while 8 (36%) showed progression of disease (treatment non-responders), 4 weeks after the start of treatment. Results: ELF KL-6 levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.011), whereas there was a marginal increase in the treatment non-responders group (P = 0.049). ELF CEA levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.004), whereas there was no significant change in the treatment non-responders group. For both markers, neither the serum levels nor the levels in contralateral ELF showed any significant changes in either group of patients. Conclusions: Both KL-6 and CEA levels in ELF near the tumour predicted tumour response in NSCLC patients treated with gefitinib, whereas serum levels did not. Intrabronchial epithelial lining fluid levels of KL-6 and CEA near tumours, as assessed by bronchoscopic microsampling, predicted tumour response in patients with advanced non-small cell lung cancer who were treated with gefitinib, whereas serum levels did not.

AB - Background and objective: Both Krebs von den Lungen-6 (KL-6) and carcinoembryonic antigen (CEA) are known to be tumour markers in non-small cell lung cancer (NSCLC). The aim of the present study was to assess whether or not intrabronchial epithelial lining fluid (ELF) levels of these markers predicted tumour response better than serum levels in patients with advanced NSCLC treated with gefitinib. Methods: ELF samples were obtained both from near the tumour and from the contralateral lung using a bronchoscopic microsampling technique, before and 2 weeks after the start of gefitinib treatment. Serum samples were taken concurrently. Among the 22 patients enrolled in the study, 14 (64%) showed partial responses or stabilization of disease with gefitinib treatment (treatment responders), while 8 (36%) showed progression of disease (treatment non-responders), 4 weeks after the start of treatment. Results: ELF KL-6 levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.011), whereas there was a marginal increase in the treatment non-responders group (P = 0.049). ELF CEA levels near the tumour decreased significantly after 2 weeks in the treatment responders group (P = 0.004), whereas there was no significant change in the treatment non-responders group. For both markers, neither the serum levels nor the levels in contralateral ELF showed any significant changes in either group of patients. Conclusions: Both KL-6 and CEA levels in ELF near the tumour predicted tumour response in NSCLC patients treated with gefitinib, whereas serum levels did not. Intrabronchial epithelial lining fluid levels of KL-6 and CEA near tumours, as assessed by bronchoscopic microsampling, predicted tumour response in patients with advanced non-small cell lung cancer who were treated with gefitinib, whereas serum levels did not.

KW - carcinoembryonic antigen

KW - epithelial lining fluid

KW - Krebs von den Lungen-6

KW - non-small cell lung cancer

KW - tumour response

UR - http://www.scopus.com/inward/record.url?scp=79960782519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960782519&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2011.02009.x

DO - 10.1111/j.1440-1843.2011.02009.x

M3 - Article

C2 - 21651645

AN - SCOPUS:79960782519

VL - 16

SP - 976

EP - 982

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 6

ER -